Evidence map›Paper›PMID 42753135›Full record

ArticleOphthalmology and therapy2026

Early Macular Leakage Resolution Is Associated with Extended Faricimab Dosing in Retinal Vein Occlusion: A BALATON/COMINO Post Hoc Analysis.

Christiana Dinah, Harit K Bhatt, Hemal Mehta, Masahiko Shimura, Ivan J Suner, Xun Xu, Nicholas Dagincourt, Liliana P Paris, Joern Schweitzer, Carl J Danzig

2 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04740905 phase3completednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion

TypeinterventionalSponsorHoffmann-La RocheRan2021 to 2023Enrolled553ConditionsMacular Edema, Branch Retinal Vein OcclusionArmsFaricimab, Aflibercept, Sham Procedure
NCT04740931 phase3completednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

TypeinterventionalSponsorHoffmann-La RocheRan2021 to 2023Enrolled729ConditionsMacular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein OcclusionArmsFaricimab, Aflibercept, Sham Procedure
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christiana DinahOphthalmology Department, London North West University Healthcare, NHS Trust, Central Middlesex Hospital, London, UK. christiana.dinah@nhs.net.ORCID http://orcid.org/0000-0002-0815-4771
Harit K BhattUniversity of Illinois at Chicago, Chicago, IL, USA.
Hemal MehtaStrathfield Retina Clinic, Sydney, Australia.ORCID http://orcid.org/0000-0002-0606-9004
Masahiko ShimuraDepartment of Ophthalmology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
Ivan J SunerRetina Associates of Florida, Tampa, FL, USA.
Xun XuSchool of Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Minhang District, Shanghai, China.
Nicholas DagincourtEverest Clinical Research, Bridgewater, NJ, USA.
Liliana P ParisGenentech, Inc., South San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-9312-9924
Joern SchweitzerF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Carl J DanzigThe Advanced Retina Institute, Bonita Springs, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMacular leakage (ML) is a biomarker of disease activity and, in retinal vein occlusion (RVO), is associated with poor vision outcomes. Faricimab, a dual angiopoietin-2 (Ang-2)/vascular endothelial growth factor (VEGF)-A inhibitor, has demonstrated efficacy and durability in RVO. This post hoc analysis of BALATON/COMINO examined the association between week 24 ML resolution and extended faricimab dosing intervals and vision outcomes achieved at week 68 in patients with RVO.

methodsBALATON and COMINO (NCT04740905/NCT04740931) were identically designed, phase 3, randomized trials that evaluated the efficacy and safety of faricimab in patients with branch or central/hemiretinal RVO, respectively. Patients initially received faricimab 6 mg every 4 weeks (Q4W) or aflibercept 2 mg Q4W; then from weeks 24-72, all patients received faricimab 6 mg up to Q16W according to a modified treat-and-extend regimen. This analysis included patients who remained in the study at week 68 and had a fluorescein angiography ML reading at week 24.

resultsAmong 989 patients, 502 had ML resolution (≤ 1 mm

conclusionsML resolution at week 24 was associated with extended faricimab dosing intervals and improved vision at week 68 in patients with RVO in the BALATON/COMINO clinical trials. CLINICALTRIALS: GOV IDENTIFIERS: NCT04740905, NCT04740931.

Indexed as

AfliberceptAngiopoietin-2BALATONBiomarkerCOMINODurabilityFaricimabMacular leakageRetinal vein occlusionVascular stability

Identifiers

PMID42753135

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.